When your patient is diagnosed with a myeloproliferative neoplasm, they will have a lot of questions, especially about the prognosis.
The prognosis depends not only on the patient's age and general health, but also on the MPN subtype, and therefore the mutation status. CALR and JAK2 V617F are important prognostic biomarkers (2) which can help you to assess your patient's future.
Rely on ipsogen for best-in-class biomarker solutions, complete workflows which save time and costs, sensitive and precise assays, and robust and accurate testing for results you can trust.